This article was originally published in The Gray Sheet
Executive SummaryU.S. shipments of the coronary stent for treatment of free perforations in native coronary vessels or saphenous vein bypass grafts are expected to commence in the second quarter following FDA humanitarian device exemption approval Jan. 10. The device will be marketed by the Swiss firm's 50-rep U.S. sales force. The market for the $2,200 stent is estimated at 3,000-4,000 units annually
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.